This site is intended for healthcare professionals
News

Interim analysis of the phase III ALPINE trial comparing Brukinsa to ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma to be reported at EHA 2021 virtual congress.-BeiGene

Read time: 1 mins
Last updated:2nd Jun 2021
Published:2nd Jun 2021
BeiGene, Ltd. announced that results from the interim analysis of the Phase III ALPINE trial comparing Brukinsa (zanubrutinib) to ibrutinib (Imbruvica) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will be reported in an oral presentation as part of the Presidential Symposium at the 26th European Hematology Association 2021 (EHA2021) Virtual Congress.
Condition: CLL/SLL
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest